MX394462B - ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS. - Google Patents
ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS.Info
- Publication number
- MX394462B MX394462B MX2018008557A MX2018008557A MX394462B MX 394462 B MX394462 B MX 394462B MX 2018008557 A MX2018008557 A MX 2018008557A MX 2018008557 A MX2018008557 A MX 2018008557A MX 394462 B MX394462 B MX 394462B
- Authority
- MX
- Mexico
- Prior art keywords
- n3pglu
- amyloid beta
- beta peptide
- peptide antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos para Aß N3pGIu humano, composiciones que comprenden tales anticuerpos Aß N3pGlu y métodos para usar tales anticuerpos Aß N3pGlu para el tratamiento de una enfermedad caracterizada por deposición de Aß que incluye enfermedad de Alzheimer clínica o pre-clínica, síndrome de Down y angiopatía amiloide cerebral clínica o pre-clínica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662279268P | 2016-01-15 | 2016-01-15 | |
| PCT/US2017/012795 WO2017123517A1 (en) | 2016-01-15 | 2017-01-10 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008557A MX2018008557A (es) | 2018-09-18 |
| MX394462B true MX394462B (es) | 2025-03-11 |
Family
ID=57966094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008557A MX394462B (es) | 2016-01-15 | 2017-01-10 | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9944696B2 (es) |
| EP (1) | EP3402817B1 (es) |
| JP (1) | JP6634158B2 (es) |
| KR (1) | KR102141969B1 (es) |
| CN (2) | CN108473566B (es) |
| AR (2) | AR107290A1 (es) |
| AU (1) | AU2017207250B2 (es) |
| CA (1) | CA3007000C (es) |
| EA (1) | EA037784B1 (es) |
| ES (1) | ES2968255T3 (es) |
| IL (1) | IL259748B2 (es) |
| JO (1) | JOP20170004B1 (es) |
| MX (1) | MX394462B (es) |
| TW (1) | TWI634126B (es) |
| WO (1) | WO2017123517A1 (es) |
| ZA (2) | ZA201803396B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| AU2017308159B2 (en) | 2016-08-12 | 2023-08-10 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| CN111954531A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化培美曲塞及其用途 |
| EP3749312A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF |
| WO2019157125A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated methotrexate and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| CN111954530A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
| WO2019160733A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| US12048766B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| WO2019160736A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2020193644A1 (en) * | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| PE20241471A1 (es) | 2021-10-29 | 2024-07-17 | Lilly Co Eli | Compuestos y metodos dirigidos a la interleucina-34 |
| TW202334210A (zh) | 2021-10-29 | 2023-09-01 | 美商美國禮來大藥廠 | 靶向介白素-34之化合物及方法 |
| CA3236504A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| KR20240099348A (ko) | 2021-10-29 | 2024-06-28 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
| CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
| IL321331A (en) | 2022-12-22 | 2025-08-01 | Bioarctic Ab | Antibody that binds to ABETAPE3 |
| WO2025228315A1 (en) * | 2024-04-28 | 2025-11-06 | Jacobio Pharmaceuticals Co., Ltd. | Anti-n3pglu amyloid beta antibodies and uses thereof |
| WO2025237397A1 (zh) * | 2024-05-16 | 2025-11-20 | 江苏恒瑞医药股份有限公司 | 抗N3pGlu Aβ抗体及其医药用途 |
| US20250388664A1 (en) | 2024-06-20 | 2025-12-25 | Bioarctic Ab | Bispecific binding molecule |
| CN118459583B (zh) * | 2024-07-11 | 2024-09-10 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| AU2009257170B2 (en) | 2008-06-12 | 2014-06-12 | Affiris Ag | Compounds for treating symptoms associated with Parkinson's disease |
| US20110182809A1 (en) | 2008-07-09 | 2011-07-28 | University Of Zurich | Method of Promoting Neurogenesis |
| NZ590563A (en) | 2008-07-21 | 2012-06-29 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) * | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| LT3339323T (lt) * | 2010-08-12 | 2020-02-10 | Eli Lilly And Company | Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas |
| AU2014233615B2 (en) * | 2010-08-12 | 2016-08-11 | Eli Lilly And Company | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
| WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
-
2017
- 2017-01-03 JO JOP/2017/0004A patent/JOP20170004B1/ar active
- 2017-01-04 AR ARP170100014A patent/AR107290A1/es active IP Right Grant
- 2017-01-04 TW TW106100110A patent/TWI634126B/zh active
- 2017-01-10 WO PCT/US2017/012795 patent/WO2017123517A1/en not_active Ceased
- 2017-01-10 CN CN201780006700.3A patent/CN108473566B/zh active Active
- 2017-01-10 AU AU2017207250A patent/AU2017207250B2/en active Active
- 2017-01-10 EP EP17703491.5A patent/EP3402817B1/en active Active
- 2017-01-10 US US15/402,268 patent/US9944696B2/en active Active
- 2017-01-10 EA EA201891286A patent/EA037784B1/ru unknown
- 2017-01-10 MX MX2018008557A patent/MX394462B/es unknown
- 2017-01-10 CN CN202210627760.XA patent/CN114891100B/zh active Active
- 2017-01-10 IL IL259748A patent/IL259748B2/en unknown
- 2017-01-10 CA CA3007000A patent/CA3007000C/en active Active
- 2017-01-10 JP JP2018529131A patent/JP6634158B2/ja active Active
- 2017-01-10 KR KR1020187019854A patent/KR102141969B1/ko active Active
- 2017-01-10 ES ES17703491T patent/ES2968255T3/es active Active
-
2018
- 2018-05-22 ZA ZA2018/03396A patent/ZA201803396B/en unknown
-
2019
- 2019-02-26 ZA ZA2019/01207A patent/ZA201901207B/en unknown
-
2024
- 2024-04-26 AR ARP240101072A patent/AR132544A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017207250B2 (en) | 2019-04-18 |
| JP2019507107A (ja) | 2019-03-14 |
| CN114891100A (zh) | 2022-08-12 |
| CA3007000A1 (en) | 2017-07-20 |
| IL259748B (en) | 2022-11-01 |
| ZA201901207B (en) | 2022-05-25 |
| CN108473566B (zh) | 2022-06-17 |
| US9944696B2 (en) | 2018-04-17 |
| CN108473566A (zh) | 2018-08-31 |
| US20170204171A1 (en) | 2017-07-20 |
| BR112018011308A2 (pt) | 2018-11-27 |
| CA3007000C (en) | 2021-07-27 |
| EP3402817B1 (en) | 2023-10-18 |
| TW201739761A (zh) | 2017-11-16 |
| CN114891100B (zh) | 2024-05-03 |
| WO2017123517A1 (en) | 2017-07-20 |
| TWI634126B (zh) | 2018-09-01 |
| MX2018008557A (es) | 2018-09-18 |
| IL259748B2 (en) | 2023-03-01 |
| ZA201803396B (en) | 2025-08-27 |
| EP3402817A1 (en) | 2018-11-21 |
| EA201891286A1 (ru) | 2018-12-28 |
| JP6634158B2 (ja) | 2020-01-22 |
| JOP20170004B1 (ar) | 2022-09-15 |
| AR107290A1 (es) | 2018-04-18 |
| IL259748A (en) | 2018-07-31 |
| EA037784B1 (ru) | 2021-05-20 |
| AU2017207250A1 (en) | 2018-06-07 |
| KR102141969B1 (ko) | 2020-08-06 |
| ES2968255T3 (es) | 2024-05-08 |
| KR20180086268A (ko) | 2018-07-30 |
| AR132544A2 (es) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394462B (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS. | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| GEAP202115055A (en) | Anti-cd27 antibodies | |
| CU24498B1 (es) | Anticuerpos de factor xi | |
| HUE053239T2 (hu) | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére | |
| DK3134386T3 (da) | Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
| DK3452100T3 (da) | FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
| LT3124048T (lt) | Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui | |
| LT3458045T (lt) | Ebselenas, skirtas naudoti menjero ligos gydymui | |
| IL270927B (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| UY36347A (es) | Compuestos y su uso como inhibidores de bace | |
| EP3672593C0 (en) | DRUGS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO VASOCONSTRICTION | |
| DK3288949T3 (da) | Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom | |
| PL3515409T3 (pl) | Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych | |
| KR20180085033A (ko) | 피부 질환 치료용 약학적 제형 및 이의 제조 방법 | |
| FR3052669B1 (fr) | Prothese biologique destinee au traitement des hernies parastomales | |
| EP3390351C0 (en) | NOVEL BICYCLIC COMPOUNDS FOR USE AS MEDICINES, IN PARTICULAR FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| EP3322481A4 (en) | TREATMENT OF ROTATOR COIL DRESSES | |
| DK3866775T3 (da) | Cysteamin til anvendelse i behandling af lungesygdomme |